A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor
NCT ID: NCT06166472
Last Updated: 2023-12-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1
72 participants
INTERVENTIONAL
2023-12-12
2026-07-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AK132
Each subject will receive a single dose of AK132 every 2-week cycle (Q2W).
AK132
IV infusion, specified dose on specified days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AK132
IV infusion, specified dose on specified days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Males or females aged ≥ 18 to ≤ 75 years at the time of signing informed consent.
3. Histologically and/or cytologically confirmed locally advanced unresectable or metastatic malignant solid tumors.
4. The interval between the end of the last systemic anti-tumor treatment and the first dose should be at least 3 weeks.
5. Subjects in the dose expansion phase are required to provide tumor tissue samples.
6. At least one measurable tumor lesion per RECIST v1.1.
7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
8. Life expectancy ≥ 3 months.
9. Adequate organ function as assessed in the laboratory tests.
10. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and agree to take effective contraception measures during the study drug administration and within 120 days after the last dose. Male patients with female partners of childbearing potential must agree to take effective contraception measures during the study drug administration and within 120 days after the last dose.
Exclusion Criteria
2. Presence of clinically symptomatic pleural effusion, pericardial effusion, or ascites requiring frequent drainage (≥ 1/month).
3. Patients who, in the opinion of the investigator, have symptoms or signs suggestive of clinically unacceptable deterioration of the primary disease at the time of screening.
4. gastrointestinal perforation or gastrointestinal fistula within 6 months before the first dose.
5. clinically significant bleeding symptoms or a clear tendency to bleed within 4 weeks before the first dose.
6. Active malignant tumors within the past 3 years, except for tumors in this study and scured local tumors.
7. History of hemolytic anemia due to any cause within 3 months before the first dose of study drug.
8. Have a history of defects in red blood cell or hemoglobin production or metabolism.
9. Major surgery other than the diagnosis of solid tumors within 28 days prior to the first dose or major surgery is expected during the study.
10. Clinically significant cardiovascular or cerebrovascular disease.
11. Presence of ≥ Grade 2 peripheral neuropathy as defined by NCI CTCAE v5.0.
12. Presence of active diverticulitis.
13. Patients with serious neurological or psychiatric disorders.
14. Pregnant or lactating women.
15. Patients who received palliative local therapy for any tumor lesions within 2 weeks prior to the first dose;and Chinese herbal medicine or traditional Chinese medicinal products with anti-tumor indications within 2 weeks prior to the first dose.
16. Serious adverse reactions in subjects who have previously received anti-PD-1/PD-L1/CTLA-4 or any other immunotherapy or immuno-oncology (IO) drug.
17. Patients who require systemic treatment with glucocorticoids (\> 10 mg/day prednisone or equivalent) or other immunosuppressive drugs within14 days prior to the first dose.
18. Unresolved toxicities during prior anti-tumor therapy with the exception of alopecia/pigmentation.
19. Subjects with a known history of severe hypersensitivity to other monoclonal antibodies. A known history of allergy or hypersensitivity to AK132 or any of its components.
20. Previous use of any antineoplastic drug targeting the CD47-SIRPα pathway or Claudin18.2.
21. Active autoimmune disease requiring systemic treatment within 2 years prior to the start of study treatment, or autoimmune diseases that may relapse or require scheduled treatment as judged by the Investigator.
22. Known active pulmonary tuberculosis.
23. Patients with active hepatitis B or active hepatitis C.
24. Known medical history of immunodeficiency or positive HIV test.
25. Known presence of interstitial lung disease or noninfectious pneumonitis that is currently symptomatic or requires prior systemic glucocorticoid therapy that, in the judgment of the Investigator, may affect the assessment or management of toxicity related to study treatment.
26. Patients with active infection, including those requiring intravenous antibiotics or antifungal therapy for 2 weeks prior to first dose, and unexplained fever during screening (CTCAE≥1, except those determined by the investigator to be neoplasmic).
27. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
28. Live vaccines were administered within 28 days prior to the first dose or were planned to be administered during the study period.
29. Concurrent participation in another clinical study, unless it is an observational, non-interventional clinical study or the follow-up period of an interventional study.
30. Any condition that, in the opinion of the Investigator, may result in a risk when receiving the study drug, or would interfere with the evaluation of the study drug or the safety of patients, or the interpretation of the study results.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Akeso
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ruihua Xu, M.D.
Role: PRINCIPAL_INVESTIGATOR
Name:Sun Yat-Sen University Cancer Center, Guangzhou, China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China
Sun Yat-Sen University Cancer Center, Guangzhou, China
Guangzhou, Guangdong, China
Southern Medical University Nanfang Hospital
Guangzhou, Guangdong, China
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital
Wuhan, Hubei, China
Xiangyang Central Hospital
Xiangyang, Hubei, China
Hunan Provincial Cancer Hospital
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yu Lin, M.D.
Role: primary
Ruihua Xu, M.D.
Role: primary
Guoxin Li, M.D.
Role: primary
Jingqi Chen, M.D.
Role: primary
Tao Zhang, M.D.
Role: primary
Tienan Yi, M.D.
Role: primary
Yongchang Zhang, M.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AK132-101
Identifier Type: -
Identifier Source: org_study_id